Seeking Alpha
28 May 2026, 17:35 UTC · 19w ago
Verdict
Headline leans bullish. We score TGTX +1.00 across three claims.
Score confirms the headline.
Leans bullish
From its wording — no explicit rating
+1.00strongly bullish
More positive than 99% of ticker scores this week
Search tags
What the story claims
3 claims · scored −1 bearish … +1 bullish
TG Therapeutics raised 2026 BRIUMVI sales guidance to $885–$900 million.
So whatUpward revisions to long-term revenue guidance directly increase valuation models and signal strong commercial scalability.
More positive than 99% of claims this week
The Phase 3 ENHANCE trial was successful for single 600 mg IV BRIUMVI dosing.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
More positive than 93% of claims this week
BRIUMVI achieved 63% year-over-year sales growth in Q1.
So whatStrong current growth validates market adoption and provides a foundation for future guidance.
More positive than 79% of claims this week
Which stocks this story touches
More positive than 99% of ticker scores this week
The company is rated as a 'Strong Buy' with robust revenue growth and successful Phase 3 trial results.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Seeking Alpha
1h ago
+40.5%
Price agrees with the score
$55.07 vs $39.20 close before publication (May 27) · not market-adjusted
TGTX chart →
